British National Formulary September 2023 Update

This update contains 5 significant changes, 2 new monographs, 2 new preparations, 4 deleted monographs and 2 deleted preparations.

Significant Changes:

• Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia [MHRA/CHM advice] (advice in calcium gluconate).
• Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.
• Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions.
• Drugs that cause sedation: new pharmacodynamic effects drug group; see Appendix 1 interactions.
• Non-steroidal anti-inflammatory drugs: potential risks following prolonged use after 20 weeks of pregnancy [MHRA/CHM advice].

New Monographs:

• Omvoh® [mirikizumab].
• Roclanda® [latanoprost with netarsudil].

New Preparations: Azelair® [azelastine hydrochloride]; Naloxone hydrochloride 1.26 mg nasal spray.

Deleted Monographs: Capreomycin; Clemastine; Glutaraldehyde; Moxisylyte.

Deleted Preparations: Aminophylline modified-release tablet; Sodium cromoglicate pressurised inhalation.